More on CYCC
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Net loss | -8.95M |
| Accretion of interest on notes payable, net of amortization of debt premium | |
| Amortization of investment premiums, net | |
| Change in valuation of derivative | |
| Change in valuation of warrants | |
| Warrant re-pricing | |
| Depreciation and amortization | |
| Amortization of intangible assets | |
| Fixed asset impairment | |
| Goodwill and intangibles impairment | |
| Unrealized foreign exchange loss | |
| Deferred revenue | |
| Compensation for warrants issued to non employees | |
| Shares issued for IP rights | |
| (Gain) loss on disposal of property, plant and equipment | |
| Stock based compensation | 614K |
| Provision for restructuring | |
| Amortization of issuance costs of Preferred Ordinary "C" shares | |
| Prepaid expenses, inventory and other current assets | 629K |
| Accounts payable, accrued liabilities and other current liabilities | |
| Net cash used in operating activities | |
| Purchase of ALIGN | |
| Purchase of property, plant and equipment | 0 |
| Proceeds from sale of property, plant and equipment | |
| Purchase of short-term investments | |
| Redemptions of short-term investments, net of maturities | |
| Net cash provided by (used in) investing activities | |
| Payment of capital lease obligations | |
| Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs | |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 5.24M |
| Net proceeds from stock options and warrants exercised | |
| Payment of preferred stock dividend | -150K |
| Repayment of government loan | |
| Government loan received | |
| Loan received from Cyclacel Group Plc | |
| Proceeds of committable loan notes issued from shareholders | |
| Loans received from shareholders | |
| Cash and cash equivalents assumed on stock purchase | |
| Costs associated with stock purchase | |
| Net cash provided by (used in) financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | |
| Net increase (decrease) in cash and cash equivalents | -2.41M |
| Cash and cash equivalents at beginning of period | 20.44M |
| Cash and cash equivalents at end of period | 18.03M |
| Interest | |
| Taxes | |
| Interest | |
| Acquisitions of equipment purchased through capital leases | |
| Issuance of common shares in connection with license agreements | |
| Issuance of Ordinary shares on conversion of bridging loan | |
| Issuance of Preferred Ordinary "C" shares on conversion of secured convertible loan notes and accrued interest | |
| Issuance of Ordinary shares in lieu of cash bonus | |
| Issuance of other long term payable on ALIGN acquisition | |
Entities mentioned with CYCC
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Irina Koffler | View Related Stories »
- Definitive Agreement | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Roth Capital | View Related Stories »
- Show More...
